ABSTRACT
Growing evidence identifies histamine as a key player in allergic responses, but the reports relating serum histamine to tolerance are scarce and inconclusive. This study investigated the relationship of circulating histamine to the tolerant phenotype in allergic beekeepers. The results showed a positive correlation between the serum levels of histamine and specific immunoglobulin G4 (sIgG4) to honeybee venom, but not with total IgE or sIgE. Interestingly, both sIgG4 and histamine levels were negatively correlated with the time since the last bee sting. In contrast to total IgE and sIgE, serum sIgG4 and histamine levels followed comparable patterns, being higher in tolerant/recently stung individuals and lower in the least frequently stung subgroup. The data obtained in this pilot study associated, for the first time, serum histamine levels with allergen tolerance in allergic individuals and provided the lead for further considering the putative immunomodulatory properties of histamine in allergic responses.
Subject(s)
Allergens/immunology , Bee Venoms/immunology , Histamine/blood , Hypersensitivity/blood , Hypersensitivity/immunology , Immunoglobulin G/blood , Immunoglobulin G/immunology , Insect Bites and Stings , Female , Humans , Immune Tolerance , Immunoglobulin E/blood , Immunoglobulin E/immunology , Male , Pilot ProjectsABSTRACT
Background: Allergic rhinitis is a global health problem which causes major illness and represents a risk factor for asthma. The primary aim of the study was to record the clinical pattern of allergic rhinitis and its temporal relation with asthma in a Greek population. Methods: Three-hundred and sixteen subjects with documented diagnosis of allergic rhinitis in a two-year period were included in this study. All participants completed a standardised questionnaire with full retrospective epidemiological data for rhinitis; in addition, serum IgE measurement and skin prick tests with 22 common inhalant allergens were carried out, while spirometry was performed in subjects with self-reported or doctor-diagnosed asthma. All subjects with at least one positive skin test were included in study analysis. Results: One-hundred and sixty five out of 316 patients (49.1%) stated self reported-asthma while in 63/316 (19.9%) asthma was documented with spirometry. One hundred out of 165 (60.6%) had rhinitis as first clinical manifestation while in 24/165 (14.5%) asthma symptoms appeared first; the remaining 31/165 (24.9%) reported simultaneous onset of upper and lower airways' symptoms. About 68.5% were sensitised to seasonal allergens exclusively, while 50% were sensitised to ≥1 of Parietaria, grasses sp., Olea eur. The duration of rhinitis in the subpopulation of patients with self-reported asthma (n=165) was significantly higher compared with non-asthmatics (mean=3.22 years, p<0.001). Survival analysis for the estimation of asthma onset showed that the mean time interval with rhinitis only is 16.6 years (median 12 years, incidence 0.0596). Conclusions: The unique environmental conditions and the aerobiology of each area clearly affect the clinical features of respiratory allergy
No disponible
Subject(s)
Humans , Rhinitis, Allergic, Seasonal/epidemiology , Asthma/epidemiology , Respiratory Hypersensitivity/epidemiology , Comorbidity , Retrospective Studies , Spirometry , Skin TestsABSTRACT
BACKGROUND: Allergic rhinitis is a global health problem which causes major illness and represents a risk factor for asthma. The primary aim of the study was to record the clinical pattern of allergic rhinitis and its temporal relation with asthma in a Greek population. METHODS: Three-hundred and sixteen subjects with documented diagnosis of allergic rhinitis in a two-year period were included in this study. All participants completed a standardised questionnaire with full retrospective epidemiological data for rhinitis; in addition, serum IgE measurement and skin prick tests with 22 common inhalant allergens were carried out, while spirometry was performed in subjects with self-reported or doctor-diagnosed asthma. All subjects with at least one positive skin test were included in study analysis. RESULTS: One-hundred and sixty five out of 316 patients (49.1%) stated self reported-asthma while in 63/316 (19.9%) asthma was documented with spirometry. One hundred out of 165 (60.6%) had rhinitis as first clinical manifestation while in 24/165 (14.5%) asthma symptoms appeared first; the remaining 31/165 (24.9%) reported simultaneous onset of upper and lower airways' symptoms. About 68.5% were sensitised to seasonal allergens exclusively, while 50% were sensitised to ≥ 1 of Parietaria, grasses sp., Olea eur. The duration of rhinitis in the subpopulation of patients with self-reported asthma (n=165) was significantly higher compared with non-asthmatics (mean=3.22 years, p<0.001). Survival analysis for the estimation of asthma onset showed that the mean time interval with rhinitis only is 16.6 years (median 12 years, incidence 0.0596). CONCLUSIONS: The unique environmental conditions and the aerobiology of each area clearly affect the clinical features of respiratory allergy.
Subject(s)
Allergens/immunology , Asthma/epidemiology , Pollen/immunology , Rhinitis, Allergic, Seasonal/epidemiology , Adolescent , Adult , Asthma/diagnosis , Asthma/physiopathology , Comorbidity , Female , Follow-Up Studies , Greece , Humans , Incidence , Male , Mediterranean Region , Parietaria , Retrospective Studies , Rhinitis, Allergic, Seasonal/diagnosis , Rhinitis, Allergic, Seasonal/physiopathology , Skin Tests , SpirometrySubject(s)
Cholinesterase Inhibitors/adverse effects , Desensitization, Immunologic , Drug Hypersensitivity/prevention & control , Exanthema/chemically induced , Hypersensitivity, Delayed/chemically induced , Phenylcarbamates/adverse effects , Administration, Cutaneous , Aged, 80 and over , Alzheimer Disease/drug therapy , Cholinesterase Inhibitors/administration & dosage , Cholinesterase Inhibitors/immunology , Drug Hypersensitivity/etiology , Exanthema/prevention & control , Female , Humans , Phenylcarbamates/administration & dosage , Phenylcarbamates/immunology , Rivastigmine , Skin TestsABSTRACT
Coronary artery disease is associated with increased serum levels of cholesterol, triglycerides and LDL, but low levels of HDL. The most potent agent capable of reversing this trend is the vitamin nicotinic acid (niacin). However, compliance even with extended-release preparations and addition of acetylsalicylic acid (ASA) is hampered by the development of a feeling of erythema and burning ("flush"), especially on the face. We recently showed that the natural flavonoids quercetin and luteolin can eliminate "flush", as well as inhibit both niacin-induced plasma prostaglandin D2 (PGD2) and serotonin increase in an animal model. We conducted a pilot clinical study in humans. Four normal male subjects received (a) 1 g immediate release niacin either alone or after (b) the dietary formulation (Algonot-plus) containing 150 mg quercetin per capsule. Subjects completed a visual scale (1 = no, 5 = worst response) symptom assessment. Erythema and burning sensation scores were both 4.75+/-0.50 and lasted for 3.63+/-1.11 hours. After Algonot-plus administration, both scores were reduced to 2.5+/-0.58 and lasted only for 1.68+/-0.70 hours. Quercetin also inhibited methylnicotinate-induced human mast cell PGD2 release. These preliminary results suggest that quercetin could reduce niacin-induced "flush" in humans.
